Clinical trial
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
NCT00436293 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00436293 |
|---|---|
| Title | Taxotere + Cisplatin in Nasopharyngeal Carcinoma |
| Official title | A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nasopharyngeal Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel, Cisplatin |
| Enrollment | 61 |
| Start date | Dec 1, 2002 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Feb 19, 2007 |
| Last update posted | Nov 17, 2010 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: